DePuy Orthopaedics Newswire

Comprehensive Real-Time News Feed for DePuy Orthopaedics.

Results 1 - 20 of 623 in DePuy Orthopaedics

  1. GE Names Ex-Vanguard Chairman as Lead Board DirectorRead the original story

    1 hr ago | Wall Street Journal

    General Electric Co. on Wednesday named John J. Brennan, a former chairman of mutual fund Vanguard Group, as lead independent director on the company's board, a signal the company is carefully considering investor interests.

    Comment?

  2. Johnson & Johnson recalls kids, adults medicineRead the original story

    Jul 8, 2010 | FOX16

    The company is withdrawing some production lots that were made before Jan. 15 and sold in the U.S., Puerto Rico, Fiji, Guatemala, the Dominican Republic, Trinidad and Tobago, and Jamaica.

    Comment?

  3. Study Backs Thousands of DePuy Pinnacle Hip Lawsuit Claims of Device...Read the original story

    12 hrs ago | PRWeb

    ... reactions in other parts of the body, including the heart, central nervous system, and kidneys. (In re: DePuy Orthopaedics Inc. Pinnacle Hip Implant Product Liability Litigation, MDL No. 2244) In January 2013, the U.S. Food & Drug Administration ...

    Comment?

  4. Smartphone apps to help patients take their medsRead the original story

    Monday | Salt Lake Tribune

    Several smartphone apps are available to help patients take their medications as prescribed.

    Comment?

  5. Charity Miles App Nominated for Webby: Walking for A Good CauseRead the original story w/Photo

    Wednesday Apr 16 | Beth's Blog

    Over the past year, I have been using a fitbit to help me incorporate more activity in my life.

    Comment?

  6. Amanda Peet: Every Child's Wishes And Dreams MatterRead the original story w/Photo

    Monday | The Huffington Post

    This post is part of the Global Moms Relay . Every time you share this post, Johnson & Johnson will donate $1 , up to $250,000, to the Global Moms Relay, to help improve the health and well-being of moms and kids worldwide in support of MAMA , Shot@Life , and Girl Up .

    Comment?

  7. Kids, Hispanics Most Gung-ho RecyclersRead the original story

    Monday | MediaPost

    In a study meant to explore how willing Americans are to extend their green behavior beyond the kitchen trashcan, children and Hispanics are emerging as the country's most enthusiastic recyclers.

    Comment?

  8. Johnson & Johnson A Clear Pick In A Turbulent MarketRead the original story

    Monday | Seeking Alpha

    JNJ stock has gained 9% this year, outperforming the S&P, and showing the company's staying power in tricky times.

    Comment?

  9. Warfarin's Loss is Johnson & Johnson's GainRead the original story w/Photo

    Monday | The Motley Fool

    Warfarin has long been doctor's go-to medicine for guarding against blood clots in post-operative or cardiovascular disease patients.

    Comment?

  10. Why Gilead Sciences Is Heading To $80Read the original story

    Monday | Seeking Alpha

    Over the past four quarters, Gilead has posted an average profit increase of 25% year-over-year, including a 63% surge in profit in the February quarter.

    Comment?

  11. Russia baby products market: Johnson & Johnson continues to dominate during 2012Read the original story w/Photo

    Monday | PR-inside.com

    The company held a 19% value share, having a wide presence in all regions of Russia.

    Comment?

  12. Will Edwards Snatch Defeat From The Jaws Of Its Victory Over Medtronic?Read the original story

    Monday | Forbes.com

    On the heels of a sweeping victory in the courts over its rival Medtronic, Edwards Lifesciences is poised to dominate the TAVR market- the revolutionary new catheter technology that offers some patients with life-threatening aortic valve disease an alternative to chest-splitting surgery.

    Comment?

  13. Scripps Looks To PartnerRead the original story w/Photo

    Sunday | Chemical & Engineering News

    In a bid to create more productive partnerships with industry, Scripps Research Institute has launched Scripps Advance, a vehicle for turning promising projects from inside and outside Scripps's labs into drug candidates.

    Comment?

  14. Analysts point to new phase of bull marketRead the original story w/Photo

    Sunday | Business Times

    Searching for yield: Traders sold highfliers such as Google in the wake of their earnings and rotated into companies that reported steadier - if less spectacular - growth, such as General Electric and Johnson & Johnson.

    Comment?

  15. Why Low-Volatility Stocks Might Not Work in the Next CrashRead the original story

    Sunday Apr 20 | The Motley Fool

    One strategy that many investors use to protect themselves against pullbacks is to focus on stocks that have lower volatility than the overall market, counting on them to fall more gently than the S&P 500 in the event of trouble.

    Comment?

  16. Johnson & Johnson Starts Construction On $300 Million China PlantRead the original story

    Friday Apr 18 | BioSpace

    For J&J, the new facility is its biggest single investment in a plant and its largest production facility .

    Comment?

  17. Belgium digestive remedies market: Janssen-Cilag the dominant industry player during 2012Read the original story w/Photo

    Friday Apr 18 | PR-inside.com

    Janssen-Cilag was the undisputed leader in a fragmented competitive environment in the Belgium digestive remedies market in 2012.

    Comment?

  18. Scripps scientists win $2M research grantRead the original story

    Thursday Apr 17 | Business Journal

    Scripps Research Institute scientists in Jupiter won a $2.1 million grant to search for an anti-diabetes drug.

    Comment?

  19. How your green business can encourage consumers to recycleRead the original story w/Photo

    Thursday Apr 17 | Examiner.com

    Nearly three-quarters of consumers consistently recycle in the home, but only about half do so in rooms beyond the kitchen.

    Comment?

  20. Argus Increases Johnson & Johnson Price Target to $116.00Read the original story

    Thursday Apr 17 | AmericanBankingNews.com

    The firm currently has a "buy" rating on the stock. Argus' target price suggests a potential upside of 16.94% from the stock's previous close.

    Comment?